Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics

Alentov, Marshutina Nv, Sergeeva Ns, Korneeva Ia, Novikova Eg, Serum tumor markers CA125 and HE4 in ovarian cancer patients Voprosy onkologii. ,vol. 59, pp. 12- 21 ,(2013)

C. Vollbrecht, K. König, L. Heukamp, R. Büttner, M. Odenthal, Molekularpathologie der Lunge Der Pathologe. ,vol. 34, pp. 16- 24 ,(2013) , 10.1007/S00292-012-1704-7

Jianfei Wang, Hongying Yang, Yinchen Shen, Shuai Wang, Dongmei Lin, Li Ma, Xiaohong Han, Yuankai Shi, Direct sequencing is a reliable assay with good clinical applicability for KRAS mutation testing in colorectal cancer. Criminal Behaviour and Mental Health. ,vol. 13, pp. 89- 97 ,(2013) , 10.3233/CBM-130334

Aberrant expression of Notch3 predicts poor survival for hepatocellular carcinomas. BioScience Trends. ,vol. 7, pp. 152- 156 ,(2013) , 10.5582/BST.2013.V7.3.152

Xia Pu, Yuanqing Ye, Xifeng Wu, Development and validation of risk models and molecular diagnostics to permit personalized management of cancer. Cancer. ,vol. 120, pp. 11- 19 ,(2014) , 10.1002/CNCR.28393

Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey, Karin S Kassahn, Felicity Newell, Michael CJ Quinn, Stephen Kazakoff, Kelly Quek, Charlotte Wilhelm-Benartzi, Ed Curry, Huei San Leong, Australian Ovarian Cancer Study Group, Anne Hamilton, Linda Mileshkin, George Au-Yeung, Catherine Kennedy, Jillian Hung, Yoke-Eng Chiew, Paul Harnett, Michael Friedlander, Michael Quinn, Jan Pyman, Stephen Cordner, Patricia O’Brien, Jodie Leditschke, Greg Young, Kate Strachan, Paul Waring, Walid Azar, Chris Mitchell, Nadia Traficante, Joy Hendley, Heather Thorne, Mark Shackleton, David K Miller, Gisela Mir Arnau, Richard W Tothill, Timothy P Holloway, Timothy Semple, Ivon Harliwong, Craig Nourse, Ehsan Nourbakhsh, Suzanne Manning, Senel Idrisoglu, Timothy JC Bruxner, Angelika N Christ, Barsha Poudel, Oliver Holmes, Matthew Anderson, Conrad Leonard, Andrew Lonie, Nathan Hall, Scott Wood, Darrin F Taylor, Qinying Xu, J Lynn Fink, Nick Waddell, Ronny Drapkin, Euan Stronach, Hani Gabra, Robert Brown, Andrea Jewell, Shivashankar H Nagaraj, Emma Markham, Peter J Wilson, Jason Ellul, Orla McNally, Maria A Doyle, Ravikiran Vedururu, Collin Stewart, Ernst Lengyel, John V Pearson, Nicola Waddell, Anna deFazio, Sean M Grimmond, David DL Bowtell, Whole-genome characterization of chemoresistant ovarian cancer Nature. ,vol. 521, pp. 489- 494 ,(2015) , 10.1038/NATURE14410

Dustin M. Walters, James M. Lindberg, Sara J. Adair, Timothy E. Newhook, Catharine R. Cowan, Jayme B. Stokes, Cheryl A. Borgman, Edward B. Stelow, Bryce T. Lowrey, Maria E. Chopivsky, Tona M. Gilmer, John T. Parsons, Todd W. Bauer, Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib Neoplasia. ,vol. 15, pp. 143- 155 ,(2013) , 10.1593/NEO.121712

Rachel N. Grisham, Gopa Iyer, Karuna Garg, Deborah DeLair, David M. Hyman, Qin Zhou, Alexia Iasonos, Michael F. Berger, Fanny Dao, David R. Spriggs, Douglas A. Levine, Carol Aghajanian, David B. Solit, BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. ,vol. 119, pp. 548- 554 ,(2013) , 10.1002/CNCR.27782

Laura Ardighieri, Felix Zeppernick, Charlotte G Hannibal, Russell Vang, Leslie Cope, Jette Junge, Susanne K Kjaer, Robert J Kurman, Ie-Ming Shih, Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants The Journal of Pathology. ,vol. 232, pp. 16- 22 ,(2014) , 10.1002/PATH.4293

Kjetil Soreide, Marianne Berg, EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discovery Medicine. ,vol. 14, pp. 207- 214 ,(2012)